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Abstract: Non-alcoholic fatty liver disease (NAFLD), characterised by early lipid accumulation and subsequent in-
flammation in the liver, is becoming a worldwide challenge due to its increasing prevalence in developing and de-
veloped countries. This study aimed to investigate the role of CXC chemokine ligand 16 (CXCL16) and its receptor 
CXC chemokine receptor 6 (CXCR6) in NAFLD under inflammation. We used IL-1β stimulation in human hepatoblas-
toma cell line (HepG2) for in vitro studies and casein injection in apolipoprotein E knockout mice in vivo to induce 
inflammatory stress. The effects of inflammation on cholesterol accumulation were examined by histochemical 
staining and a quantitative intracellular cholesterol assay. The gene and protein expression of molecules involved 
in CXCL16/CXCR6 pathway and extracellular matrix (ECM) were examined by real-time polymerase chain reaction 
(PCR) and Western blotting. The fluorescence intensity of reactive oxygen species (ROS) was assessed by flow 
cytometry. Results showed that significantly elevated levels of serum amyloid protein A in casein-injected mice con-
firmed the successful induction of inflamed NAFLD model. Inflammation significantly increased lipid accumulation 
in livers compared with the high-fat diet group and the controls. Furthermore, inflammation increased the expres-
sion of CXCL16, CXCR6, and adisintegrin and metalloproteinase domain-containing protein 10 (ADAM10) in livers, 
accompanied with increased ECM expression and ROS production. These effects were further confirmed by in vitro 
studies. Interestingly, CXCL16 gene knockdown in HepG2 cells induced by CXCL16 siRNA resulted in decreased 
lipid accumulation, ECM excretion, and ROS production. These findings demonstrated that inflammation-mediated 
activation of CXCL16/CXCR6 is involved in the progression of NAFLD. 
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Introduction 
Non-alcoholic fatty liver disease (NAFLD) is 
increasingly recognised as a leading cause of 
liver dysfunction and cirrhosis in the developed 
world and is a part of the spectrum of meta-
bolic diseases associated with obesity, dyslipi-
demia, insulin resistance, and type 2 diabetes 
mellitus [1, 2]. NAFLD presents as a spectrum 
of pathologies ranging from benign steatosis 
defined by accumulation of triglycerides and 
other glycerophospolipids in hepatocytes and 
progresses to non-alcoholic steatohepatitis 
(NASH) characterised by the development of 
concomitant inflammation in the liver [3]. NASH 
is a unique liver microenvironment marked by 
accumulation of triglycerides, characteristic 
pathologic findings such as Mallory bodies and 
the infiltration of inflammatory cells [4]. As time 
goes on, NASH progresses to end-stage liver 
disease with fibrosis and cirrhosis, and even 
hepatocellular cancer. Conventional models 
include a “two-hit” and “multi-hit” hypothesis of 
NAFLD in which the dysregulated lipid metabo-
lism and insulin resistance are considered the 
“first hit” and the following “second hit” or “mul-
ti-hit” likely involve oxidative stress, lipid peroxi-
dation, and subsequent inflammatory respons-
es [5]. However, the exact mechanisms of in- 
flammatory stress in the progression of NAFLD 
have not been completely elucidated.
Liver inflammation in general is tightly con-
trolled by chemokines, which are peptide medi-
ators that stimulate the chemotaxis of target 
cells through specific G protein-coupled recep-
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tors [6]. Recently, a novel chemokine, CXC che- 
mokine ligand 16 (CXCL16) was found, which 
was found to be widely expressed in immune 
cells, smooth muscle cells, and endothelial 
cells [7]. Matloubian [8] and Wilbanks [9] dem-
onstrated that CXCL16 exists in a transmem-
brane-bound and soluble form. Transmembrane-
bound CXCL16 has two functions [10]: as a cell 
surface adhesion molecule, it might mediate 
T-cell adhesion to the endothelium; as a novel 
scavenger receptor, it mediates the uptake of 
atherogenic lipoproteins by macrophages and 
smooth muscle cells [11]. Furthermore, trans-
membrane-bound CXCL16 can be released to 
its soluble form upon digestion by adisintegrin 
and metalloproteinase domain-containing pro-
tein 10 (ADAM10) [12]. Soluble CXCL16 can re- 
cruit activated immune cells expressing CXC 
chemokine receptor 6 (CXCR6), the receptor 
of CXCL16, including CD8+T cells, CD4+T cells, 
natural killer (NK) cells, invariant natural killer T 
(NKT) cells, plasma cells and monocytes. So- 
luble CXCL16 enhances transendothelial mes-
enchymal stem cell migration [13] and facili-
tates immune cell migration to sites of inflam-
mation, such as inflamed liver [14].
Recently, several lines of evidence have shown 
that activation of CXCL16 is involved in the pro-
gression of kidney diseases. Serum CXCL16 
levels were higher in patients with lupus nephri-
tis [15], diabetic nephropathy and nephritic syn-
drome [16] when compared with healthy peo-
ple. In addition, CXCL16 and its receptor CXCR6 
play crucial roles in the pathogenesis of athero-
sclerosis by mediating oxidative low-density li- 
poprotein (oxLDL) engulfment by macrophages 
and smooth muscle cells, which then develop 
into cholesterol-filled foam cells. CXCL16 acts 
as chemoattractants, activating and attracting 
CD8+T cells to sites of inflammation [11]. More- 
over, Wehr et al. [17] showed that hepatic NKT 
cells become CXCR6-dependent early upon 
injury, thereby accentuating the inflammatory 
response in the liver and promoting hepatic 
fibrogenesis. Interfering with CXCL16/CXCR6 
might, therefore, have therapeutic potential in 
liver fibrosis.
Although plenty of studies have demonstrated 
the role of the CXCL16/CXCR6 pathway in kid-
ney diseases, atherosclerosis, and liver inju-
ries, little is known about its function in the pro-
gression of NAFLD, especially under subse-
quent inflammation during the second hit pha- 
se. Our previous study demonstrated that in- 
creased mammalian target of rapamycin com-
plex 1 (mTORC1) activity mediated by inflamma-
tion exacerbates the progression of NAFLD 
by disrupting low-density lipoprotein receptor 
expression at the transcriptional and posttran-
scriptional levels [18]. Therefore, this study 
aimed to investigate the role of the CXCL16/
CXCR6 pathway in NAFLD under the condition 
of inflammation in vivo and in vitro.
Materials and methods
Animals 
Male apolipoprotein E knockout (ApoE KO) mice 
were kindly provided by Animal Care of Chong 
Qing Medical University. The mice were main-
tained under a constant 12-hour photoperiod 
at temperatures between 21°C and 23°C and 
were allowed free access to food and water. 
Eight-week-old ApoE KO mice were randomly 
assigned and fed with a normal diet containing 
4% fat (control group, n=8), or a high-fat diet 
containing 21% fat and 0.15% cholesterol (HF 
group, n=8), or a high-fat diet plus daily 0.5 ml 
10% casein (100 grams of casein dissolved in 
1 litre of water with 4.2 grams of sodium bicar-
bonate) subcutaneous injection (HF+casein 
group, n=8) for 8 weeks. When the experiments 
were terminated at the 8th week, the blood was 
sampled from right heart ventricle for biochem-
ical assays. Isolated liver samples were used 
for histological assessments. The protocols 
used in experiments were approved by the 
Committee on the Ethics of Animal Experiments 
of Southeast University. The methods were car-
ried out in accordance with the approved guide-
lines. All surgeries were performed under so- 
dium pentobarbital anesthesia to minimize 
suffering.
Enzyme-linked immunosorbent assay
The serum amyloid protein A (SAA) was meas-
ured using commercial kits (Invitrogen, USA).
Plasma lipid profile analysis
Using blood samples obtained from the mice at 
termination, Serum concentrations of triglycer-
ide (TG), total cholesterol (TC), high-density lipo-
protein (HDL) and LDL were determined by 
automatic analysers (Hitachi, Japan).
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Haematoxylin-eosin (HE) staining
Livers tissues embedded in paraffin were 
sectioned and dewaxed. Sections were then 
stained for 15 minutes with haematoxylin, sub-
sequently stained for 3 minutes by 1% eosin. 
After dehydration, resinene was used to seal 
the sections to transparency. The sections were 
observed under light microscopy (×400).
Filipin staining
Samples were fixed with 5% paraformaldehyde 
for 30 minutes, washed with phosphate buff-
ered saline (PBS), and incubated with freshly 
prepared Filipin solution for 30 minutes. The 
slides were then washed with PBS, a drop of 
phenylenediamine/glycerol was added, and the 
slides were mounted with cover slips and exam-
ined by laser confocal microscopy (×200).
Immunohistochemical staining
The sections embedded in paraffin were previ-
ously deparaffinised and treated with 0.3% 
endogenous peroxidase blocking solution for 
15 minutes. Sections were then treated 
sequentially with normal nonimmune animal 
serum for 30 minutes and incubated with 
anti-mouse polyclonal primary antibodies tar-
geting CD68 (Novus Biologicals Inc., Canada), 
monocyte chemotactic protein 1 (MCP-1, Santa 
Cruz Biotechnology Inc., USA), tumour necrosis 
factor-α (TNF-α, Santa Cruz Biotechnology Inc., 
USA), CXCL16 (R&D Systems Inc., USA), CXCR6 
(Novus Biologicals Inc., Canada), ADAM10 (Ab- 
cam, UK), collagen I (Abcam, UK) and α-smooth 
muscle actin (α-SMA, Abcam, UK) at 4°C over-
night. Sections were then incubated with biotin-
labelled secondary antibodies (Maixin Biotech- 
nology Ltd., China) for 30 minutes at room tem-
perature, followed by incubation with strepto-
mycete antibiotin-peroxidase for another 10 
minutes. Staining was completed by a 3-minute 
incubation with 3, 3’-diaminobenzidine sub-
strate-chromogen, which resulted in a brown-
coloured precipitate at the antigen site. Coun- 
terstaining was performed with haematoxylin. 
Immunohistochemical images were acquired 
by light microscope (×400). 
Cell culture
An established human hepatoblastoma cell 
line (HepG2, Tumour Cell Bank of the Chinese 
Academy of Sciences, China) was used in all 
experiments. The cells were cultured with 
Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing 10% fetal bovine serum (Gibco, 
USA). The cells were incubated with the condi-
tion of 5% CO2 at 37°C. At 70%-80% confluence, 
the cells were synchronised with a serum-free 
culture medium for 24 hours and subsequently 
stimulated with 30 μg/ml cholesterol (Sigma, 
USA) or with 5 ng/ml interleukin-1β (IL-1β, R&D 
systems Inc., USA) for another 24 hours.
Quantitative measurements of intracellular 
free cholesterol/cholesterol ester
Quantitative measurements of intracellular 
total and free cholesterol were measured using 
previous method [19]. Briefly, the lipids were 
extracted from collected cells by adding 1 mL of 
chloroform/methanol (2:1). After sonication, 
the lipid phase was collected from centrifuged 
samples and then dried in a vacuum, followed 
by dissolved in 2-propanol containing 10% 
Triton X-100. The amount of total cholesterol 
was calculated by checking free cholesterol 
converted from cholesterol ester by cholesterol 
ester hydrolase (Sigma, USA). The concentra-
tion of total and free cholesterol per sample 
was analysed using a standard curve and nor-
malised against total cell protein. The concen-
tration of cholesterol ester was calculated by 
subtracting the amount of free cholesterol from 
the total cholesterol.
CXCL16 siRNA transfection
HepG2 cells were cultured in six-well plates 
and transiently transfected with the CXCL16 
siRNA or an empty vector siRNA (Cell Signaling 
Technology, USA) using Lipofectamine 2000 
(Invitrogen, USA) in accordance with the manu-
facturer’s protocol. Briefly, 2 μL of CXCL16 
siRNA was mixed with 5 μL of Lipofectamine 
2000 and applied to the cells. The transfected 
cells were incubated at room temperature for 
15 minutes and were then seeded in a well 
containing 250 μL of Opti-MEM medium (Gibco 
Life Technologies, USA). At the indicated time 
points, the cells were harvested and examined 
by Filipin staining, immunofluorescent staining, 
real-time polymerase chain reaction (PCR), and 
Western blotting.
Confocal microscopy
HepG2 cells cultured in a glass bottom dish 
were washed, fixed, and permeabilised. The 
cells were then incubated with CXCL16 (R&D 
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Systems Inc., USA) and ADAM10 (Abcam, UK), 
followed by the secondary fluorescent antibo- 
dies (donkey anti-goat Alexa Fluor 488 for 
CXCL16 and donkey anti-rabbit Alexa Fluor 
594 for ADAM10). After washing, the cells 
were examined by laser confocal microscope 
(Olympus, Japan). The colocalisation efficiency 
of CXCL16 with ADAM10 was quantified using 
Image-Pro Plus software, version 6.0 (×400).
Reactive oxygen species (ROS) production as-
say
HepG2 cells grown on cover slips were treat- 
ed by stimulation for 24 hours, washed with 
Dulbecco’s PBS and incubated with media con-
taining 50 μmol/l 5-(and-6)-chloromethyl-27-di-
chlorodihydrofluoroscein diacetate acetylester 
(CM-H2DCFDA) for 6 hours in the dark. Culture 
dishes were transferred to a digital microscope 
from Keyence (Neu-Isenburg, Germany) to doc-
ument and analyse ROS generation. The aver-
age intensity of ROS fluorescence was quanti-
tatively measured and analysed by flow cyto- 
metry.
Real-time PCR
Total RNA was extracted from the HepG2 cells 
and cDNA was aquired by reverse transcription 
(RT) using RNAiso Plus (Takara, Japan). Real-
α-SMA overnight at 4°C, followed by horserad-
ish peroxidase-labelled secondary antibodies 
for one hour at room temperature. β-actin was 
used as an internal sample loading control and 
was detected with a mouse monoclonal anti-
body (Santa Cruz, USA). Signals were detected 
using an advanced ECL system (GE Healthcare, 
UK). Relative protein expression levels were 
determined by normalisation against β-actin.
Statistical analysis
All the data are expressed as the means ± 
standard deviation (SD) and analysed using 
SPSS13.0 statistical software. The Student’s 
t-test was used to analyse the statistical signifi-
cance between two groups. One-way analysis 
of variance (ANOVA) was used to analyse the 
statistical significance among multiple groups. 
P<0.05 was considered to be statistically sig- 
nificant.
Results
Establishment of inflamed NAFLD model 
As shown in Figure 1A, there was a significantly 
increased plasma concentration of SAA in the 
HF+casein group compared with the control. 
Immunohistochemical staining and Western 
blotting demonstrated that there was increased 
Table 1. The primers used for real-time PCR
Genes Primer sequences
CXCL16 5’-GACTCTATGTTGCCCAGGCTGTTAT-3’-sense
5’-GCAGTGGCTGGTTAGTCCTATGTT-3’-antisense
CXCR6 5’-CAAGAGCCTACTGGGCATCTACAC-3’-sense
5’-TGGCCTTAACCACTACAATGAAAC-3’-antisense
ADAM10 5’-GAACTCTGCCATTTCACTCTGTCAT-3’-sense
5’-GCATGTTCTTCTTGAGGTATCTGTG-3’-antisense
MCP-1 5’-CAGCCAGATGCAATCAATGCC-3’-sense
5’-TGGAATCCTGAACCCACTTCT-3’-antisense
TNF-α 5’-AGGACACCATGAGCACTGAAAGC-3’-sense
5’-AAGGAGAAGAGGCTGAGGAACAAG-3’-antisense
Collagen I 5’-CGATGGATTCCAGTTCGAGTATG-3’-sense
5’-TGTTCTTGCAGTGGTAGGTGATG-3’-antisense
a-SMA 5’-GACAATGGCTCTGGGCTCTGTAA-3’-sense
5’-ATGCCATGTTCTATCGGGTACTTCA-3’-antisense
Fibronectin 5’-GAGCTGCACATGTCTTGGGAAC-3’-sense
5’-GGAGCAAATGGCACCGAGATA-3’-antisense
β-actin 5’-AAAGACCTGTACGCCAACAC-3’-sense
5’-GTCATACTCCTGCTTGCTGAT-3’-antisense
time PCR was performed on an ABI7300 
Real-time PCR System (Applied Biosys- 
tems, USA) using SYBR Green dye. The 
primers used for Real-time PCR are shown 
in Table 1. β-actin served as an internal 
reference gene. The results were analy- 
sed using Sequence Detection software, 
version 1.4 (Applied Biosystems, USA). 
The relative gene expression of each tar-
get gene was quantified against a stand-
ard curve. 
Western blotting
The identical total protein extracted from 
the HepG2 cells was isolated by gel elec-
trophoresis and transferred onto poly- 
vinylidene difluoride membranes. The 
membranes were then blocked by block-
ing buffer for one hour at room tempera-
ture. The membranes were subjected to 
Western blotting using anti-human poly-
clonal antibodies against MCP-1, TNF-α, 
CXCL16, CXCR6, ADAM10, collagen I, and 
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Figure 1. Establishment of inflamed NAFLD model. ApoE KO mice were fed with a normal diet containing 4% fat 
(Control), a high-fat diet containing 21% fat and 0.15% cholesterol (HF group), or a HF diet with 10% casein injection 
(HF+casein group) for 8 weeks (n=8). The levels of SAA in the serum of three groups were measured by enzyme 
linked immunosorbent assay (A). The results are expressed as the means ± SD (n=8). **P<0.01 vs. Control. The 
protein expression of CD68, TNF-α, and MCP-1 in the livers of the mice was measured by immunohistochemical 
staining (B, brown colour, original magnification ×400). The protein expression of TNF-α and MCP-1 in the livers of 
the mice was further checked by Western blotting. The identical total protein extracted from liver tissues was iso-
lated by gel electrophoresis and transferred onto polyvinylidene difluoride membranes. The membranes were sub-
jected to Western blotting using anti-mouse polyclonal antibodies against TNF-α, MCP-1, or β-actin which was used 
as an internal control. The histogram represents the means ± SD of the densitometric scans of the protein bands 
from the mice in each group, normalised by comparison with β-actin (C and D). *P<0.05 vs. Control, **P<0.01 vs. 
Control. HepG2 cells were treated without (Control) or with 30 µg/ml of cholesterol (CHO group), 5 ng/ml of IL-1β (IL-
1β group), 30 µg/ml of cholesterol + 5 ng/ml of IL-1β (CHO+IL-1β group), 30 µg/ml of cholesterol + 5 ng/ml of IL-1β 
+ CXCL16 siRNA (CHO+IL-1β + siCXCL16 group), or 30 µg/ml of cholesterol + 5 ng/ml of IL-1β + CXCL16 siRNA nega-
tive control (CHO+IL-1β + sicontrol group) for 24 hours. Total RNA was extracted from the HepG2 cells and cDNA 
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protein expression of TNF-α, MCP-1, and CD68 
in the livers of the HF+casein group compared 
with the HF group (Figure 1B-D). These findings 
suggest that systemic and local inflammation 
was successfully established in casein-injected 
mice. Furthermore, increased CD68 protein 
expression in the livers of casein-injected mice 
showed the infiltration of microphages subse-
quent to an inflammatory response. Results 
from in vitro studies further confirmed that 
IL-1β increased the mRNA and protein expres-
sion of TNF-α and MCP-1 in cholesterol-loaded 
HepG2 cells. Interestingly, the gene knockdown 
of CXCL16 expression by CXCL16 siRNA mark-
edly decreased the expression of TNF-α and 
MCP-1 in IL-1β-treated HepG2 cells with choles-
terol loading (Figure 1E-G). 
Inflammation induced lipid accumulation in 
hepatic cells in vivo and in vitro 
As shown in Table 2, plasma concentrations of 
TG, TC, and LDL in the HF group were signifi-
cantly increased compared with the control. 
Although serum TG, TC, and LDL levels were 
decreased in the casein-injected ApoE KO mice 
compared with the HF group. HE staining and 
Filipin staining demonstrated that there was 
more significant lipid accumulation in the livers 
of casein-injected ApoE KO mice compared 
with the HF group (Figure 2A-C). Results from 
in vitro studies further demonstrated that IL- 
1β stimulation contributed to lipid droplet 
accumulation in HepG2 cells (Figure 2D and 
2E). However, inhibition of CXCL16 expression 
by CXCL16 siRNA prevented lipid accumulation 
in HepG2 cells (Figure 2DV). Quantitative analy-
sis of intracellular cholesterol further confirmed 
these results (Figure 2C and 2E). These find-
ings suggest that CXCL16 might be involved in 
the inflammation-mediated lipid accumulation 
in HepG2 cells. 
Inflammation induced the activation of 
CXCL16/CXCR6 pathway in hepatic cells
Therefore we examined the effects of inflam- 
mation on the CXCL16/CXCR6 pathway in the 
presence or absence of lipid loading. As dem-
onstrated by immunohistochemical staining, 
immunofluorescent staining, real-time PCR, 
and Western blotting, the results from in vivo 
and in vitro studies showed that inflammation 
exacerbated the increased mRNA and protein 
expression of CXCL16, CXCR6, and ADAM10 in 
hepatic cells induced by lipid loading compared 
with the control (Figure 3A-F). As expected, IL- 
1β up-regulated the expression of CXCL16, 
CXCR6, and ADAM10 in HepG2 cells (Figure 
3G). However, these effects were inhibited by 
CXCL16 siRNA, suggesting that the CXCL16/
CXCR6 pathway is activated by cholesterol 
loading and inflammation. In addition, we also 
noticed that the expression of ADAM10 con-
stantly increased after cholesterol loading and 
IL-1β treatment, whereas CXCL16 siRNA could 
not prevent its expression.
Effects of CXCL16/CXCR6 pathway activation 
on the expression of ECM components and 
ROS production in hepatic cells
Collagen I and α-SMA are the main components 
of extracellular matrix (ECM) in livers. Therefore, 
we then examined the effects of inflammation 
on ECM expression in hepatic cells. We found 
was aquired by reverse transcription. The mRNA expression of TNF-α and MCP-1 in HepG2 cells was determined by 
real-time PCR. β-actin served as the housekeeping gene (E). Results represent the means ± SD.**P<0.01 vs. Control, 
##P<0.01 vs. CHO+IL-1β. The protein expression of TNF-α and MCP-1 in HepG2 cells was checked by Western blot-
ting. The identical total protein extracted from the HepG2 cells was isolated by gel electrophoresis and transferred 
onto polyvinylidene difluoride membranes. The membranes were subjected to Western blotting using anti-human 
polyclonal antibodies against MCP-1, TNF-α, or anti-human monoclonal antibody against β-actin which was used as 
an internal control. The histogram represents the means ± SD of the densitometric scans for TNF-α and MCP-1, nor-
malised by comparison with β-actin (F and G). *P<0.05 vs. Control, **P<0.01 vs. Control, ##P<0.01 vs. CHO+IL-1β.
Table 2. Biochemical data in the three groups 
of mice (means ± SD)
Indexes
Control 
group (n=8)
HF group 
(n=8)
HF+casein 
group (n=8)
TG (mmol/l) 3.1±0.6 7.5±2.0** 3.4±0.8##
TC (mmol/l) 13.7±2.7 27.8±4.0** 14.9±1.9##
HDL (mmol/l) 1.0±0.4 0.8±0.3 1.7±0.5*,##
LDL (mmol/l) 5.8±1.5 11.6±3.0** 9.5±1.3**,#
Compared to the controls, the mice fed with a high fat diet 
developed hyperlipidemia. The mice injected with 10% 
casein showed decreased plasma lipid concentrations 
compared with the HF group. TG: triglyceride, TC: total 
cholesterol, HDL: high-density lipoprotein, LDL: low density 
lipoprotein. *P<0.05 vs. Control, **P<0.01 vs. Control, 
#P<0.05 vs. HF group, ##P<0.01 vs. HF group.
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Figure 2. Inflammation induced lipid accumulation in hepatic cells in vivo and in vitro. ApoE KO mice were fed with a normal diet containing 4% fat (Control), a high 
fat diet containing 21% fat and 0.15% cholesterol (HF group), or with 10% casein injection (HF+casein group) for 8 weeks (n=8). The lipid accumulation in livers was 
checked by HE staining (A, I-III, ×400), Filipin staining (B, IV-VI, ×200). Quantitative assay of intracellular free cholesterol and cholesterol ester was used to further 
evaluate lipid accumulation in liver tissues (C). The results are expressed as the means ± SD (n=8). **P<0.01 vs. Control. HepG2 cells were treated without (Control) 
or with 30 µg/ml of cholesterol (CHO group), 5 ng/ml of IL-1β (IL-1β group), 30 µg/ml of cholesterol + 5 ng/ml of IL-1β (CHO+IL-1β group), 30 µg/ml of cholesterol 
+ 5 ng/ml of IL-1β + CXCL16 siRNA (CHO+IL-1β + siCXCL16 group), or 30 µg/ml of cholesterol + 5 ng/ml of IL-1β + CXCL16 siRNA negative control (CHO+IL-1β + 
sicontrol group) for 24 hours. The lipid accumulation in HepG2 cells was checked by Filipin staining (D, I-VI, ×200). Quantitative assay of intracellular free cholesterol 
and cholesterol ester was used to check lipid accumulation as described in the section of materials and methods (E). Values are expressed as the means ± SD of 
triplicate wells from four experiments. **P<0.01 vs. Control, ##P<0.01 vs. CHO+IL-1β.
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Figure 3. Inflammation induced the activation of the CXCL16/CXCR6 pathway in hepatic cells. ApoE KO mice were 
fed with a normal diet containing 4% fat (Control) a high fat diet containing 21% fat and 0.15% cholesterol (HF 
group), or a high fat diet with a 10% casein injection (HF+casein group) for 8 weeks (n=8). The protein expression 
of CXCL16/CXCR6 pathway components in the three groups of mice was checked by immunohistochemistry (A I-IX, 
×400) and Western blotting. The identical total protein extracted from liver tissues was isolated by gel electrophore-
sis and transferred onto polyvinylidene difluoride membranes. The membranes were subjected to Western blotting 
using anti-mouse polyclonal antibodies against CXCL16, CXCR6, ADAM10, or β-actin which was used as an internal 
control. The histogram represents the means ± SD of the densitometric scans for the protein bands of CXCL16/
CXCR6 pathway components, normalised by comparison with β-actin (B and C). **P<0.01 vs. Control. HepG2 cells 
were treated without (Control) or with 30 µg/ml of cholesterol (CHO group), 5 ng/ml of IL-1β (IL-1β group), 30 µg/
ml of cholesterol + 5 ng/ml of IL-1β (CHO+IL-1β group), 30 µg/ml of cholesterol + 5 ng/ml of IL-1β + CXCL16 siRNA 
(CHO+IL-1β + siCXCL16 group), or 30 µg/ml of cholesterol + 5 ng/ml of IL-1β + CXCL16 siRNA negative control 
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(CHO+IL-1β + sicontrol group) for 24 hours. Total RNA was extracted from the HepG2 cells and cDNA was acquired 
by reverse transcription. The mRNA expression of CXCL16, CXCR6, and ADAM10 in HepG2 cells was determined 
by real-time PCR. β-actin served as the housekeeping gene (D). Results represent the means ± SD. *P<0.05 vs. 
Control, **P<0.01 vs. Control, #P<0.05 vs. CHO+IL-1β, ##P<0.01 vs. CHO+IL-1β. The protein expression of CXCL16, 
CXCR6, and ADAM10 in HepG2 cells was checked by Western blotting. The identical total protein extracted from 
the HepG2 cells was isolated by gel electrophoresis and transferred onto polyvinylidene difluoride membranes. The 
membranes were subjected to Western blotting using anti-human polyclonal antibodies against CXCL16, CXCR6, 
ADAM10, or anti-human monoclonal antibody against β-actin which was used as an internal control. The histogram 
represents means ± SD of the densitometric scans for CXCL16, CXCR6 and ADAM10, normalised by comparison 
with β-actin (E and F). *P<0.05 vs. Control, **P<0.01 vs. Control, #P<0.05 vs. CHO+IL-1β, ##P<0.01 vs. CHO+IL-1β. 
Immunofluorescent staining of CXCL16 and ADAM10 in HepG2 cells (G). The cells were stained with DAPI to visual-
ise nuclei (blue), and with Alexa Fluor 488 and Alexa Fluor 594 to visualise the distribution of ADAM10 (green) and 
CXCL16 (red) proteins. 
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that inflammation exacerbated the increase 
of collagen I and α-SMA protein expression in 
hepatic cells compared with the control, as 
confirmed by immunohistochemical staining 
(Figure 4AI-VI). Western blotting analysis fur-
ther confirmed the results from the immunohis-
tochemical staining (Figure 4B and 4C). Results 
from the in vitro study showed that the mRNA 
and protein expression of collagen I and α-SMA 
were significantly increased in IL-1β-stimulated 
hepatic cells with or without cholesterol load- 
ing compared with the control. However, these 
effects were inhibited by CXCL16 siRNA (Figure 
4D-F). These results suggest that inflamma-
tion-mediated ECM production occurs via the 
activation of the CXCL16/CXCR6 pathway.
To investigate the effects of inflammation on 
ROS production in HepG2 cells with or without 
cholesterol loading, we analysed the fluores-
cence intensity of ROS-sensitive 5-(and-6)-chlo-
romethyl-2’7’-dichlorodihydrofluorescein diace-
tate after the treatment of cholesterol loading 
and IL-1β stimulation. As shown in Figure 4G 
and 4H, IL-1β significantly increased ROS pro-
duction in HepG2 cells mediated by cholesterol 
loading. However, ROS production was signifi-
cantly prevented by CXCL16 siRNA, which sug-
gests that CXCL16/CXCR6 pathway activation 
may play crucial roles in inflammation-mediat-
ed ROS production from HepG2 cells. 
Discussion 
According to the hypothesis of NAFLD, lipid 
accumulation caused by lipid disorder is the 
“first hit” and the subsequent inflammation is 
the “second hit”, which promotes the develop-
ment of NAFLD. CXCL16, as a scavenger recep-
tor, adhesion molecule, and chemokine, has 
cross-talk with inflammation and lipid disor-
ders. In this study, we mainly observed the role 
of the CXCL16/CXCR6 pathway in the progres-
sion of NAFLD. We successfully induced sys-
temic inflammation by subcutaneously inject-
ing the high-fat-fed ApoE KO mice with 10% 
casein, as shown by the significantly increased 
plasma SAA level compared with the HF group. 
In addition, immunohistochemical staining and 
Western blotting showed that the expression 
levels of CD68, MCP-1, and TNF-α were signifi-
cantly increased in the livers of casein-injected 
high-fat-diet fed mice. It is well-known that 
CD68 is a specific biomarker of macrophages 
[20]. These findings suggested that systemic 
and local inflammation was established, which 
confirmed that an inflamed NAFLD model was 
successfully induced. Meanwhile, serum TC, 
TG, and LDL levels in the casein-injected mice 
were lower than those in the HF group. However, 
Filipin staining and intracellular cholesterol 
quantitative assays showed that lipid accumu-
lation was significantly increased in the livers of 
Figure 4. Effects of CXCL16/CXCR6 pathway activation on the expression of ECM components in the livers of ApoE 
KO mice and in HepG2 cells. ApoE KO mice were fed with a normal diet containing 4% fat (Control), a high fat diet 
containing 21% fat and 0.15% cholesterol (HF group), or with 10% casein injection (HF+casein group) for 8 weeks 
(n=8). Immunohistochemical staining shows the expression of collagen I and α-SMA in the livers of ApoE mice (A 
I-VI, ×400). The protein expression of collagen I and α-SMA in livers was checked by Western blotting. The identical 
total protein extracted from liver tissues was isolated by gel electrophoresis and transferred onto polyvinylidene 
difluoride membranes. The membranes were subjected to Western blotting using anti-mouse polyclonal antibodies 
against collagen I, α-SMA, or β-actin which was used as an internal control. The histogram represents the means ± 
SD of the densitometric scans for the protein bands of collagen I and α-SMA, normalised by comparison with β-actin 
(B and C). **P<0.01 vs. Control. HepG2 cells were treated without (Control) or with 30 µg/ml of cholesterol (CHO 
group), 5 ng/ml of IL-1β (IL-1β group), 30 µg/ml of cholesterol + 5 ng/ml of IL-1β (CHO+IL-1β group), 30 µg/ml of 
cholesterol + 5 ng/ml of IL-1β + CXCL16 siRNA (CHO+IL-1β + siCXCL16 group), or 30 µg/ml of cholesterol + 5 ng/ml 
of IL-1β + CXCL16 siRNA negative control (CHO+IL-1β + sicontrol group) for 24 hours. Total RNA was extracted from 
the HepG2 cells and cDNA was acquired by reverse transcription. The mRNA expression of collagen I and α-SMA 
was determined by real-time PCR. β-actin served as the housekeeping gene (D). Results represent the means ± SD. 
*P<0.05 vs. Control, **P<0.01 vs. Control, #P<0.05 vs. CHO+IL-1β, ##P<0.01 vs. CHO+IL-1β. The protein expression 
of collagen I and α-SMA in HepG2 cells was checked by Western blotting. The identical total protein extracted from 
the HepG2 cells was isolated by gel electrophoresis and transferred onto polyvinylidene difluoride membranes. 
The membranes were subjected to Western blotting using anti-human polyclonal antibodies against collagen I, 
α-SMA, or anti-human monoclonal antibody against β-actin which was used as an internal control. The histogram 
represents the means ± SD of the densitometric scans for the protein bands of collagen I and α-SMA, normalised by 
comparison with β-actin (E and F). **P<0.01 vs. Control, #P<0.05 vs. CHO+IL-1β, ##P<0.01 vs. CHO+IL-1β. HepG2 
cells were washed with Dulbecco’s phosphate buffered saline and incubated in the dark for 6 hours with 50 μmol/l 
5-(and-6)-chloromethyl-2’7’-dichlorodihydrofluorescein diacetate (green fluorescence) (G). The fluorescence inten-
sities of ROS production was quantified by Cell Quest software. Data represent the means ± SD (H). **P<0.01 vs. 
Control, ##P<0.01 vs. CHO+IL-1β.
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casein-injected high-fat-diet ApoE KO mice. 
These results demonstrated that inflammatory 
stress markedly exacerbated lipid accumula-
tion and induced lipid redistribution from the 
circulation to the hepatic cells, which was con-
firmed by our previous studies [21]. 
It has been reported that CXCL16 is involved 
in the pathogenesis of inflammatory diseases, 
such as atherosclerosis [22], cardiomyopathy 
[23], and membranous nephropathy [15]. In 
our study, the mRNA and protein expression 
levels of CXCL16 and CXCR6 were significantly 
increased in response to lipid loading and 
inflammatory stress. However, CXCL16 inhibi-
tion by siRNA overrode these effects, accompa-
nied by decreased lipid accumulation and re- 
duced inflammatory cytokine production, sug-
gesting that the CXCL16/CXCR6 pathway may 
be involved in the development of NAFLD. It is 
clear that as a transmembrane protein, CXCL16 
can act as a scavenger receptor for oxLDL 
uptake [24]. The accumulation of oxLDL result-
ed in foam cell formation. A recent study [25] 
showed that internalised macrophages from 
CXCL16-/- mice had significantly less oxLDL 
uptake compared to wild-type macrophages. 
Additionally, the CXCL16 level was significantly 
increased with the severity of renal injury 
caused by hypercholesterolemia and oxLDL 
generation after unilateral ureteral obstruction 
[26]. Furthermore, blocking antibodies against 
CXCL16 significantly decreased oxLDL uptake 
and reduced the development of macrophage-
derived foam cells. When CXCL16 is in soluble 
form, it can be released from the cell mem-
brane by ADAM10 and can act as a chemokine 
that attracts neutrophils and lymphocytes. Gu- 
twein et al. [15] demonstrated that pro-inflam-
matory cytokines, such as TNF-α and IFN-γ, can 
increase cellular as well as soluble CXCL16 in 
cultured human podocytes. Smith et al. [27] 
found that IL-1β can promote CXCL16 release 
in endothelial cells, suggesting that soluble 
CXCL16 could be linked to atherogenesis, not 
only as a marker of inflammation but also as a 
potential inflammatory mediator. Meanwhile, 
the pro-inflammatory factors, MCP-1 and TNF-
α, also increased in high-fat mice and choles-
terol-loaded HepG2 cells, which suggests that 
the transmembrane-bound form of CXCL16 
acts as an adhesion molecule at the same 
time. Moreover, lipid accumulation in livers and 
HepG2 cells was accompanied by increased 
expression of CXCL16 under the conditions of 
cholesterol enrichment or inflammatory stress, 
while CXCL16 siRNA inhibited these effects. 
These findings are consistent with our previous 
studies that showed that inflammatory stress 
and dyslipidemia synergise to cause organ inju-
ries [21, 28, 29]. Meanwhile, these results also 
suggest that although lipid loading and inflam-
mation both increase the expression of CXCL16, 
different stimulating factors determine the pre-
dominant form of CXCL16 and which functions 
it mainly performs. As the unique receptor of 
CXCL16, CXCR6 mediates CXCL16 signals to 
promote the adhesive function and direct 
migration of different CXCR6-positive inflam-
matory cells, leading to T lymphocyte homing 
and macrophage accumulation as well as vas-
cular smooth muscle cell proliferation [30, 31]. 
Therefore, the expression of CXCR6 is identical 
with CXCL16 in our study, which has also been 
previously shown in prostate cancer [32] and 
periodontal diseases [33].
ADAM10 is a major protease responsible for 
the conversion of CXCL16 from a membrane-
bound scavenger receptor to a soluble che- 
mokine [34]. In our study, IL-1β stimulation 
increased the expression of ADAM10 to release 
more soluble CXCL16, which is in accordance 
with the findings of other studies [12, 33]. 
Interestingly, we found that the protein expres-
sion of ADAM10 was significantly increased in 
the livers of the HF group and in cholesterol-
loaded HepG2 cells. At first glance, these find-
ings seem to be in conflict with previous publi-
cations. In human embryonic kidney (HEK) 293 
cells, increasing the cellular cholesterol con-
tent reduced the activity of ADAM10, as deter-
mined by measuring the amount of cleaved 
soluble amyloid precursor protein [35]. In hu- 
man umbilical vein endothelial cells, cholester-
ol depletion with an accompanying increase in 
the fluidity of the erythrocyte membrane mark-
edly accelerated pro-vibrio cholera cytolysin 
cleavage by ADAM10 [36]. The studies men-
tioned above examined ADAM10 in terms of its 
cleavage activity. However, fewer papers have 
investigated the expression of ADAM10. Saa- 
rela et al. [37] found that atherogenic lipids up-
regulated CXCL16 and down-regulated ADAM10 
in primary human monocyte-derived mac-
rophages, resulting in the preferential expres-
sion of CXCL16 as the transmembrane form, 
not the soulble form. Gutwein et al. [15] found 
Activation of the CXCL16/CXCR6 pathway and fatty livers
1813 Am J Transl Res 2018;10(6):1802-1816
that in kidney biopsies of patients with mem-
branous nephropathy, increased glomerular 
CXCL16 expression was accompanied by high 
level of oxLDL and decreased expression of 
ADAM10. Nevertheless, some results from 
other studies were consistent with ours. Cho- 
lesterol stimulation may also up-regulate the 
expression of ADAM10, although the cleavage 
of CXCL16 was not predominant. Schramme et 
al. [38] demonstrated that variable CXCL16 
expression and increased ADAM10 expression 
were observed in biopsy tissues from kidney 
transplanted patients with the diagnosis of 
acute interstitial rejection. Matthews et al. [39] 
showed that in human THP-1 cells, cholesterol 
enrichment increased the shedding of interleu-
kin-6 receptor (IL-6R) compared with the con-
trol. The discrepancies among different studies 
could reflect a cell-type specific effect, which 
may depend on the availability of the specific 
protease in that cell type [15]. Moreover, it has 
recently been shown that depending on the 
stimuli used, different metalloproteinases can 
regulate the release of CXCL16. In COS cells, 
phorbol 12-myristate 13-acetate induced the 
release of CXCL16, which was primarily medi-
ated by ADAM17 [15]. In the glomeruli of pa- 
tients with membranous nephropathy, increa- 
sed ADAM17 expression was detectable, and 
the knockdown of ADAM10 by siRNAs increased 
not only cellular CXCL16 expression but also 
enhanced the release of CXCL16 from human 
podocytes [15], suggesting that ADAM17 plays 
an important role in the cleavage of CXCL16 in 
patients with membranous nephropathy. Our 
study found that the protein expression of 
ADAM10 was significantly increased, but the 
change in ADAM10 mRNA expression was not 
statistically significant when stimulated by 
cholesterol loading. Actually, ADAM-mediated 
shedding occurs constitutively and after activa-
tion with a broad variety of stimuli. The shed-
ding process can be regulated at different lev-
els by mechanisms including transcriptional 
control, posttranslational modifications, enzy- 
me stability, and cellular localisation [40, 41]. 
According to our results, we propose that cho-
lesterol loading may mainly regulate ADAM10-
mediated shedding at the posttranslational 
level. Furthermore, CXCL16 siRNA has no effect 
on the expression of ADAM10. The underlying 
mechanism needs to be elucidated. Considering 
the liver tissue in vivo and HepG2 cells in vitro, 
we cannot exclude a tissue-specific effect on 
the expression of ADAM10. In fact, ADAM10 is 
over-expressed in human HepG2 cells. The siR-
NA-mediated knockdown of ADAM10 signifi-
cantly inhibited the growth, migration, and inva-
sion of HepG2 cells [42]. Pruessmeyer et al. 
[43] found that either increasing ADAM10 or 
ADAM17 activity could limit neurodegeneration 
or suppressing their activity can block inflam-
mation or tumour growth. It is clear that more 
questions need to be answered in future re- 
search efforts.
After the initial hepatic infiltration, the liver 
becomes extremely vulnerable to a series of 
hits that may follow, leading to hepatocyte in- 
jury and finally progressing from steatosis to 
NASH, and even fibrosis [44]. Xia et al. [45] 
demonstrated that in response to angiotensin 
II, CXCL16 recruits macrophages, T cells, and 
myeloid fibroblasts into the kidney, leading to 
renal fibrosis. Matsushita et al. [46] found that 
soluble CXCL16 promoted an epithelial-mesen-
chymal transition (EMT)-associated phenotype 
characterised by impaired E-cadherin produc-
tion and the induction of vimentin in vitro. Our 
study found that CXCL16 inhibition down-regu-
lated the expression of ECM components in the 
livers of ApoE KO mice and in HepG2 cells, 
showing that CXCL16 plays a pivotal role in the 
pathogenesis of liver injury and fibrosis through 
the regulation of macrophage and T cell infiltra-
tion and ECM accumulation. Gutwein et al. [16] 
demonstrated that inhibition of oxLDL uptake 
by CXCL16 blocking antibodies abrogated 
fibronectin and ROS production and restored 
α3 integrin expression in human podocytes. 
Our in vivo and in vitro studies demonstrated 
that inflammation exacerbated lipid disorder-
mediated ROS production in hepatic cells. 
Surprisingly, blocking CXCL16 expression by 
CXCL16 siRNA resulted in reduced ROS produc-
tion accordingly.
In summary, inflammation contributes to the 
progression of NAFLD through the activation 
of the CXCL16/CXCR6 pathway. The up-regulat-
ed expression of CXCL16, as a scavenger re- 
ceptor, increases oxLDL uptake to induce lipid 
accumulation in hepatic cells, resulting in the 
disruption of cholesterol homeostasis, subse-
quent ECM synthesis, and oxidative stress pro-
duction. Additionally, increased soluble CXCL- 
16 excretion, as an adhesion molecule and a 
chemokine, recruits T cell infiltration, induces 
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more inflammatory cytokine production, and 
finally accelerates the progression of NAFLD. 
Increased understanding of the mechanisms 
of the activation of CXCL16/CXCR6 pathway 
will encourage researchers to identify reliable 
strategies to prevent the progression of NAF- 
LD. Thus, CXCL16/CXCR6 pathway could be a 
potential target of drug intervention in NAFLD, 
especially in patients accompanied with chron-
ic inflammation. Under this condition, anti-
inflammatory therapy might be also essential 
for NAFLD patients.
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